 | ||
Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials. It is the enantiomer of ormeloxifene.
References
Levormeloxifene Wikipedia(Text) CC BY-SA